Welcome to our dedicated page for Immunocore Holdings Plc SEC filings (Ticker: IMCR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immunocore Holdings plc filings document the formal disclosures of an England and Wales biotechnology company with American Depositary Shares, each representing one ordinary share, listed on Nasdaq. Recent 8-K reports furnish quarterly and annual financial results, preliminary liquidity information and corporate updates through press-release exhibits.
The filing record also includes proxy materials for the annual general meeting, covering shareholder voting procedures for ordinary shares and ADSs, and Item 5.02 disclosure on R&D leadership changes and related organizational structure. These documents describe the company’s ADS and ordinary-share capital framework, governance processes, executive matters and material-event reporting tied to its commercial-stage ImmTAX platform business.
Filing: Schedule 13G/A (Amendment No. 5) reporting for Immunocore Holdings plc (CUSIP 45258D105).
Key facts: Wellington Management Group LLP and affiliated entities report beneficial ownership of 5,132,898 shares of Immunocore common stock (reported as 10.2% / 10.22% of the class). Reported ownership shows no sole voting or dispositive power; shared voting power is reported as 4,958,998 and shared dispositive power as 5,132,898. The filing notes these shares are owned of record by clients of Wellington investment advisers and identifies Vanguard Health Care Fund as an exception referenced in Item 6. The issuer address and filer addresses are included; the filing is signed by Taisia Lowe on 08/05/2025.